PHS
UBX

PFM Health Sciences’s Unity Biotechnology UBX Stock Holding History

PFM Health Sciences’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-13,519
Closed -$1.1M – 100
2019
Q1 		$1.1M Sell
13,519
-69,483
-84% -$7.88M 0.02% 90
2018
Q4 		$13.5M Buy
83,002
+15
+0% +$1.99K 0.36% 66
2018
Q3 		$12.6M Buy
82,987
+352
+0.4% +$58K 0.18% 101
2018
Q2 		$11.5M Buy
+82,635
New +$12.1M 0.18% 98

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PFM Health Sciences's UBX Position: Q2 2019 in Review

PFM Health Sciences sold out of Unity Biotechnology (UBX) in Q2 2019, closing a stake of 13,519 shares — an estimated $1.1M sold.

PFM Health Sciences first reported a position in UBX in Q2 2018 and held it in 4 quarters. The position peaked at $13.5M in Q4 2018. 58 funds tracked by Wall St. Rank hold UBX as of Q2 2019.

  • PFM Health Sciences reported no remaining Unity Biotechnology position as of Q2 2019 after selling out during the quarter.
  • PFM Health Sciences sold 13,519 Unity Biotechnology shares in Q2 2019, an estimated $1.1M.
  • PFM Health Sciences first reported a position in Unity Biotechnology in Q2 2018 and held it in 4 quarters.
  • PFM Health Sciences's Unity Biotechnology position peaked at $13.5M in Q4 2018.
  • 58 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2019.

Based on PFM Health Sciences's 13F filing for Q2 2019, filed 14 Aug 2019.